Current treatment status-Undergoing active treatment - Page 17 of 29 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

What pediatric Hodgkin lymphoma patients benefit from radiation after chemotherapy?

Posted by on Jan 3, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial examined which children with Hodgkin lymphoma benefit from radiation therapy after chemotherapy. The authors concluded that patients with a combination of bulky disease (tumors larger than 6 cm) and anemia (low levels of red blood cells) benefited most. Some background Hodgkin lymphoma is a cancer of the lymph...

Read More

Bleomycin lung toxicity is not associated with the risk of radiation lung injury in Hodgkin lymphoma

Bleomycin lung toxicity is not associated with the risk of radiation lung injury in Hodgkin lymphoma

Posted by on Dec 24, 2016 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether or not there was an increased risk of radiation pneumonitis (RP, radiation-induced lung injury) in Hodgkin lymphoma patients treated with the chemotherapy bleomycin. The authors concluded that there was no association between bleomycin lung effects and RP. Some background...

Read More

Sentinel lymph node biopsy as a way of assessing breast cancer after chemotherapy

Sentinel lymph node biopsy as a way of assessing breast cancer after chemotherapy

Posted by on Dec 24, 2016 in Breast cancer | 0 comments

In a nutshell This study investigated sentinel lymph node biopsy (SLNB) as a procedure to determine the staging of breast cancer in patients who had received neoadjuvant chemotherapy (chemotherapy given before surgery). The authors concluded that SLNB was suitable for staging of the cancer in patients with breast cancer that had not spread to the...

Read More

Hormone therapy during or after radiation therapy increases the risk of cardiovascular events

Hormone therapy during or after radiation therapy increases the risk of cardiovascular events

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...

Read More

Guidelines for treatment of ipilimumab-associated hypophysitis in advanced melanoma

Guidelines for treatment of ipilimumab-associated hypophysitis in advanced melanoma

Posted by on Nov 21, 2016 in Melanoma | 0 comments

In a nutshell This study developed guidelines for the early detection and treatment of hypophysitis (HP; inflammation of the pituitary gland), a side effect of treatment with ipilimumab. Researchers suggested that these guidelines are necessary to ensure early detection and treatment of this condition to prevent associated mortality. Some background...

Read More

Survival benefits for men treated with local therapies before starting chemotherapy

Posted by on Nov 21, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefits of administering local therapies before chemotherapy for prostate cancer. Researchers reported lower mortality risks for men treated with local therapies before chemotherapy. Some background Local therapies, such as surgery or radiation, are first-line treatments for localized (confined) prostate...

Read More

Long-term hormone therapy and cognitive function

Posted by on Nov 7, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effects of androgen deprivation therapy (ADT) on cognitive function over 3 years. Researchers reported no significant differences in cognitive function following long-term ADT compared to control participants not undergoing ADT. Some background ADT is a type of hormone therapy commonly used to treat prostate...

Read More

Skin complications associated melanoma treatment with nivolumab or pembrolizumab

Skin complications associated melanoma treatment with nivolumab or pembrolizumab

Posted by on Oct 29, 2016 in Melanoma | 0 comments

In a nutshell This study investigated the negative effects on the skin associated with the use of nivolumab (Opdivo) to treat melanoma. Researchers suggested that skin complications are the most frequent side effects but they are in most cases manageable. Some background The use of PD-1 antibodies, such as nivolumab (Opdivo) or pembrolizumab...

Read More